ATOSSA THERAPEUTICS, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
1448 NW MARKET STREET, SEATTLE, WA, 98107
Mailing Address
1448 NW MARKET STREET, SEATTLE, WA, 98107
Phone
206.588.0256
Fiscal Year End
1231
EIN
264753208
Financial Overview
FY2025
-$25.50M
Net Income
$76.44M
Total Assets
$71.08M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 31, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | March 30, 2026 | View on SEC |
| 4 Insider stock transaction report | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 25, 2026 | View on SEC |
| 10-K Annual financial report | March 25, 2026 | View on SEC |
| 8-K Current report of material events | February 20, 2026 | View on SEC |
| 424B5 Prospectus supplement | February 20, 2026 | View on SEC |
| 8-K Current report of material events | February 17, 2026 | View on SEC |
| 8-K Current report of material events | February 11, 2026 | View on SEC |
| 4/A Insider transaction amendment | January 30, 2026 | View on SEC |
Annual Reports
10-K
March 25, 2026
- Lead drug (Z)-endoxifen showed a 72% reduction in tumor size in the I-SPY 2 trial.
- Karisma Phase 2 study demonstrated up to 23.5% reduction in breast density.
Material Events
8-K
Other
February 17, 2026
High Impact
- Successfully regained Nasdaq listing compliance, removing the significant threat of delisting.
- Ensures continued market access, liquidity, and bolsters investor confidence for ATOSSA THERAPEUTICS, INC.
8-K
Strategy Change
February 11, 2026
High Impact
- Strategic pivot to high-value rare diseases (DMD, MAS) with (Z)-endoxifen, optimizing resource allocation.
- FDA Rare Pediatric Disease and Orphan Drug Designations for DMD, offering potential for a highly valuable Priority Review Voucher (PRV).
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.